| XENCOR INC. DL-,01 |
| USA |
| Gesundheit |
| US98401F1057 / A1W96L |
| XE9 (Frankfurt) / XNCR (NASDAQ) |
| FRA:XE9, ETR:XE9, XE9:GR, NASDAQ:XNCR |
| - |
| https://xencor.com/ |
|
Xencor Inc. is a clinical-stage biopharmaceutical company focused on designing and developing engineered antibody therapeutics for cancer, autoimmune disorders, and other serious diseases. The company’s XmAb protein engineering platform is used to ..
>Volltext.. |
| 1671.28 Mio. EUR |
| 1420.23 Mio. EUR |
| 93.71 Mio. EUR |
| -183.8 Mio. EUR |
| -145.8 Mio. EUR |
| -1.94 EUR |
| 151.85 Mio. EUR |
| 39.87 Mio. EUR |
| -183.72 Mio. EUR |
| 5.58 |
| -26.31% |
| 1.53% |
| - |
| - |
| - |
| - |
| XENCOR |
| 27.10.26 |